FirstHealth of the Carolinas

Clinical Trial Details

Study Title: LCCC 1029: Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With K-RAS or BRAF Mutant Metastatic Colorectal Cancer
Study Type: Interventional
Study Condition: Colorectal Cancer
Investigator: Dr. Todd Moore
Phone: (910) 715-3500
Research Coordinator: Lori DeSpain
Phone: (910) 715-2200
Eligibility Criteria: Men or women, ages 18 and older, diagnosed with metastatic colorectal cancer. For additional criteria, call the Research Coordinator or visit the study weblink.
Sponsor Organization: UNC Lineberger Comprehensive Cancer Center
Study Rationale:
Study Purpose: This randomized (2:1), multi-center, placebo-controlled, phase II efficacy study is designed to compare PFS between regorafenib + FOLFIRI chemotherapy (ARM A) versus placebo + FOLFIRI (ARM B) in patients with mCRC and KRAS or BRAF mutant disease previously treated with a FOLFOX regimen.
Study Link:
FirstHealth @ Facebook.comFirstHealth @ Twitter.comFirstHealth @ Pinterest.comFirstHealth @
Physicians Employees
Working Together, First in Quality, First in Health
Site MapPrivacy PolicyTerms & ConditionsHelp © FirstHealth of the Carolinas, Inc.